ClinicalTrials.Veeva

Menu
C

Carolina BioOncology Institute | Huntersville, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pembrolizumab
ABBV-181
Budigalimab
Nivolumab
Bevacizumab
MDX-060
ABBV-368
Etrumadenant
ABBV-927
Atezolizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

43 of 87 total trials

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerab...

Enrolling
Solid Tumor
Breast Cancer
Drug: SON-DP

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitum...

Active, not recruiting
Gastric Cancer
Ovarian Cancer
Drug: CUE-102

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or w...

Enrolling
Advanced Solid Tumor Cancer
Drug: Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI)
Drug: ABBV-CLS-484

The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein ca...

Enrolling
Solid Tumor, Adult
Drug: CRB-701

This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cuta...

Enrolling
Cutaneous T-cell Lymphoma (CTCL)
Advanced Solid Tumor
Drug: SIM1811-03

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tol...

Active, not recruiting
Advanced Solid Tumors Cancer
Drug: ABBV-927
Drug: ABBV-181

ASP1012 is a type of virus called an oncolytic virus which is used to treat some cancers.ASP1012 was changed in a laboratory to infect and kill cance...

Enrolling
Solid Tumor
Drug: ASP1012
Drug: Pembrolizumab

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: CLN-619
Drug: Pembrolizumab

This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and...

Active, not recruiting
Advanced Solid Tumor
Lymphoma
Drug: GRC 54276
Drug: GRC 54276 + Atezolizumab

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of thi...

Enrolling
Metastatic Castration-Resistant Prostate Cancer
Drug: ABBV-969

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolera...

Enrolling
Solid Tumors
Drug: Budigalimab
Drug: ABBV-303

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) an...

Active, not recruiting
Advanced Solid Tumors
Non-small-cell-lung-cancer (NSCLC)
Drug: ABBV-368
Drug: ABBV-927

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor...

Enrolling
Advanced Solid Tumor
Drug: PEEL-224

This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab...

Active, not recruiting
Solid Tumor, Unspecified, Adult
Drug: Domvanalimab
Drug: Zimberelimab

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced...

Enrolling
Endometrial Adenocarcinoma
Appendiceal Adenocarcinoma
Drug: APL-5125

An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-...

Active, not recruiting
Advanced Solid Tumors
Drug: Paclitaxel
Drug: Docetaxel

This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and prel...

Active, not recruiting
Solid Tumor
Drug: CPO-100

This clinical trial is a Phase 1/2, open-label, sequential-group, dose-escalation and cohort expansion study to determine the safety and preliminary...

Active, not recruiting
Advanced Cancer
Drug: pembrolizumab (KEYTRUDA®)
Drug: FLX475

This is a first-in-human, Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, p...

Enrolling
Pancreatic Ductal Adenocarcinoma
Non Small Cell Lung Cancer
Drug: PT199
Drug: Tislelizumab

Trial sponsors

AbbVie logo
Bristol-Myers Squibb (BMS) logo
MacroGenics logo
Arcus Biosciences logo
N
Celldex Therapeutics logo
Incyte logo
R
T
T

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems